Financial Report

22Related parties

The following transactions have been entered into with related parties:

2022 kEUR

Income from related parties

Purchases from related parties

Amounts due from related parties

Amounts due to related parties

 

 

 

 

 

Entity with control over the company

 

 

 

 

Draupnir Holding B.V. 1

 

 

 

 

 

Other related entities

 

 

 

 

Thalamus

-167

-304

Ferring Group

41,300

-38

5,918

-4

Monedula AB

191

-1,556

-10,506

Amzell B.V.

172

Amring Pharmaceuticals Inc

Bazell Pharma AG

SVAR Life Science AB

166

Nordic Pharma Ltd.

-7

1 A cash distribution of CHF 0.3 per entitled share was approved by the General Meeting in April 2022. This resulted in a cash distribution of kEUR 5,363 to Draupnir Holding B.V. in May 2022.

2021 kEUR

Income from related parties

Purchases from related parties

Amounts due from related parties

Amounts due to related parties

 

 

 

 

 

Entity with control over the company

 

 

 

 

Draupnir Holding B.V.

6,794

-221

 

 

 

 

 

Other related entities

 

 

 

 

Thalamus

-167

-404

Ferring Group

36,169

-3

2,999

Monedula AB

355

-1,224

438

-11,447

Amzell B.V.

166

Amring Pharmaceuticals Inc

9

Bazell Pharma AG

1

SVAR Life Science AB

79

Nordic Pharma Ltd.

-9

All disclosed related parties are either related through the Esperante Investments S.à r.l. ownership structure or through managerial control. Esperante Investments S.à r.l. is a higher parent company of our majority shareholder Draupnir Holding B.V.

Income from Draupnir Holding B.V. primarily relates to reimbursement of IPO recognition bonuses. Purchases from Draupnir Holding B.V. relate to service and insurance fees.

Purchases from and amounts due to Thalamus AB relate to rental of premises.

Income from the Ferring Group and amounts due from the Ferring Group relate to sale of goods.

Purchases from Monedula AB relate to the lease of premises. Income and amounts due from Monedula relate to property management fees and recharged improvements to the premises. Amounts due to Monedula AB relate to the financial liability as disclosed in Note 18.

Income from and amounts due from Amzell B.V. relate to sale of goods.

Income from SVAR Life Science AB relates to sale of goods.

During the year, no provisions for doubtful debt and no write-offs on receivables from related parties were recognized (2021: nil). No guarantees were given or received for any outstanding related party balances (2021: nil).

Transactions with key management personnel

Compensation of key management personnel of the Group:

kEUR

2022

2021

 

 

 

Salaries and short-term benefits

3,112

3,454

Post-employment benefits

292

279

Share-based payment expense

1,155

4,206

Total transactions with key management

4,559

7,939

Reference is made to Note 4 for further details on the share-based payment expense.
Key management personnel are considered all members of the Executive Committee and the Board of Directors.

This website uses cookies to ensure you get the best experience on our website.Privacy statement